Skip to Main Content
Home
Search
Study Topics
Glossary
Full Text View
Tabular View
No Study Results Posted
Related Studies
Phase III Randomized, Double-Blind, Placebo-Controlled Study of Guanfacine for Tourette Syndrome and Attention Deficit Hyperactivity Disorder
This study has been completed.
Study NCT00004376 Information provided by Office of Rare Diseases (ORD)
First Received: October 18, 1999 Last Updated: June 23, 2005
History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Tourette Syndrome
Additional conditions recognized in this trial
Attention Deficit Disorder with Hyperactivity
Syndrome
More general conditions related to this trial
Attention Deficit and Disruptive Behavior Disorders
Basal Ganglia Diseases
Brain Diseases
Central Nervous System Diseases
Disease
Genetic Diseases, Inborn
Heredodegenerative Disorders, Nervous System
Mental Disorders
Mental Disorders Diagnosed in Childhood
Movement Disorders
Nervous System Diseases
Neurodegenerative Diseases
Pathologic Processes
Tic Disorders
Interventions listed in this trial
guanfacine
More general drug interventions related to this trial
Adrenergic Agents
Adrenergic Agonists
Adrenergic alpha-Agonists
Antihypertensive Agents
Cardiovascular Agents
Molecular Mechanisms of Pharmacological Action
Neurotransmitter Agents
Pharmacologic Actions
Physiological Effects of Drugs
Therapeutic Uses
Sponsors listed in this trial
National Center for Research Resources (NCRR)
Yale University
Back to top of Main Content
